CDKN1A and B-cell non-Hodgkin lymphoma: For example, rituximab, an anti-CD20 monoclonal antibody, induces senescence in B cell lymphoma, manifested as increased SA-β-gal expression, p21/p53 signaling, and elaboration of a SASP (80, 140).